BANU K ARUN to Neoplasm Recurrence, Local
This is a "connection" page, showing publications BANU K ARUN has written about Neoplasm Recurrence, Local.
Connection Strength
0.749
-
Biomarker Modulation Study of Celecoxib for Chemoprevention in Women at Increased Risk for Breast Cancer: A Phase II Pilot Study. Cancer Prev Res (Phila). 2020 09; 13(9):795-802.
Score: 0.197
-
Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger. J Cancer Res Clin Oncol. 2009 Jan; 135(1):141-8.
Score: 0.086
-
Clinical outcomes and Oncotype DX Breast Recurrence Score? in early-stage BRCA-associated hormone receptor-positive breast cancer. Cancer Med. 2022 03; 11(6):1474-1483.
Score: 0.055
-
Outcomes After Breast Radiation Therapy in a Diverse Patient Cohort With a Germline BRCA1/2 Mutation. Int J Radiat Oncol Biol Phys. 2022 02 01; 112(2):426-436.
Score: 0.054
-
Helical Radiotherapy in Early Laryngeal Cancers Could Lead to Excess Local Recurrence: Lessons From a Phase II Prospective Study. Clin Oncol (R Coll Radiol). 2020 02; 32(2):e67-e75.
Score: 0.047
-
Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations. Breast Cancer Res Treat. 2018 Jul; 170(1):101-109.
Score: 0.042
-
Association between weight gain during adjuvant chemotherapy for early-stage breast cancer and survival outcomes. Cancer Med. 2017 Nov; 6(11):2515-2522.
Score: 0.041
-
A Comprehensive Lifestyle Randomized Clinical Trial: Design and Initial Patient Experience. Integr Cancer Ther. 2017 03; 16(1):3-20.
Score: 0.038
-
Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer. Ann Surg Oncol. 2013 Apr; 20(4):1267-74.
Score: 0.029
-
Biology, treatment, and outcome in very young and older women with DCIS. Ann Surg Oncol. 2012 Nov; 19(12):3777-84.
Score: 0.028
-
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011 Mar 01; 17(5):1082-9.
Score: 0.026
-
Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008 Aug 20; 100(16):1179-83.
Score: 0.022
-
Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer. 2006 Jan 01; 106(1):42-50.
Score: 0.018
-
Women age < or = 35 years with primary breast carcinoma: disease features at presentation. Cancer. 2005 Jun 15; 103(12):2466-72.
Score: 0.017
-
Discordance of Oncotype DX scores in synchronous bilateral and unilateral multifocal breast cancers. Breast Cancer Res Treat. 2024 Jan; 203(1):73-83.
Score: 0.015
-
Breast Radiation Therapy-Related Treatment Outcomes in Patients With or Without Germline Mutations on Multigene Panel Testing. Int J Radiat Oncol Biol Phys. 2022 02 01; 112(2):437-444.
Score: 0.013
-
Moderately Hypofractionated Radiotherapy and Androgen Deprivation Therapy for High-risk Localised Prostate Cancer: Predictors of Long-term Biochemical Control and Toxicity. Clin Oncol (R Coll Radiol). 2022 01; 34(1):e52-e60.
Score: 0.013
-
Ductal carcinoma-in-situ of the breast with subsequent distant metastasis and death. Ann Surg Oncol. 2011 Oct; 18(10):2873-8.
Score: 0.007